Department of Surgery, Huadong Hospital, affiliated with Fudan University, Shanghai, China.
Department of Surgery, Tenth People's Hospital of Tongji University, Shanghai, China.
J Am Coll Surg. 2019 Dec;229(6):541-551.e1. doi: 10.1016/j.jamcollsurg.2019.08.1446. Epub 2019 Sep 13.
The aim of this study was to compare primary efficacy indicators of a low-cost, electrospun, nanoscale P(LLA-CL)/fibrinogen patch with a porcine small intestine submucosa patch for hernia repair.
A randomized, single-blind, controlled multicenter trial was performed in 3 hospitals in Shanghai. Eligible patients (20 to 75 years old) with primary unilateral, reducible groin hernias were randomly assigned (1:1) to electrospun nanoscale P(LLA-CL)/fibrinogen patch (experimental group) or porcine small intestine submucosa (control group) patch groups. Patients were treated with the Lichtenstein technique, and the primary endpoint was hernia recurrence at 33 months after surgery. The secondary endpoints were postoperative complications including groin pain and operative site infections.
Between July 2014 and February 2016, 172 patients were assigned to experimental (n = 86) and control (n = 86) groups. At 6-month follow-up, postoperative complications occurred in 5 patients (5 of 86, 5.81%) and 2 (2 of 86, 2.35%) patients in the control and experimental groups, respectively (p < 0.05). At 33-month follow-up, recurrence was observed in 2 patients (2 of 79, 2.53%) in the control group vs none in the experimental group (0 of 78) (the 95% CI difference between the experimental and control groups was -0.93% to 6.00% and within the preset noninferior margin of Δ10%). No significant differences were found in the degree of chronic pain and complications 33 months after surgery between the 2 groups.
Because the recurrence rates and postoperative complications after 33 months were not inferior in the experimental group, we believe that the P(LLA-CL)/fibrinogen patch, as a low cost alternative, has prospects for widespread clinical use.
本研究旨在比较低成本电纺纳米级 PLLA-CL/纤维蛋白原贴片和猪小肠黏膜下层贴片在疝修补中的主要疗效指标。
在上海的 3 家医院进行了一项随机、单盲、对照的多中心试验。符合条件的(20-75 岁)单侧、可复性腹股沟疝患者(年龄)被随机分配(1:1)到电纺纳米级 PLLA-CL/纤维蛋白原贴片(实验组)或猪小肠黏膜下层(对照组)贴片组。患者采用 Lichtenstein 技术治疗,主要终点是术后 33 个月时的疝复发。次要终点是包括腹股沟疼痛和手术部位感染在内的术后并发症。
2014 年 7 月至 2016 年 2 月期间,172 名患者被分配到实验组(n=86)和对照组(n=86)。术后 6 个月随访时,对照组 5 例(5/86,5.81%)和实验组 2 例(2/86,2.35%)患者发生术后并发症(p<0.05)。术后 33 个月随访时,对照组 2 例(2/79,2.53%)患者复发,实验组无患者复发(0/78)(实验组与对照组的 95%置信区间差异为-0.93%至 6.00%,且在预设的非劣效性边界Δ10%内)。两组术后 33 个月慢性疼痛程度和并发症无显著差异。
由于实验组的复发率和术后 33 个月的并发症无差异,我们认为 PLLA-CL/纤维蛋白原贴片作为一种低成本的替代品,具有广泛临床应用的前景。